Please login to the form below
Inebilizumab
This page shows the latest Inebilizumab news and features for those working in and with pharma, biotech and healthcare.
US, EU regulators start review of Roche’s Soliris rival satralizumab
Meanwhile, another emerging rival in the NMOSD category is Viela Bio, whose inebilizumab was filed for approval with the FDA earlier this year. ... Viela thinks inebilizumab has a dosing advantage over both Soliris and satralizumab as it can be
Latest news
-
Roche presents new data in NMOSD, could challenge Alexion's Soliris
Another contender comes from Viela Bio, inebilizumab, which was filed for approval with the FDA earlier this month. ... Viela thinks inebilizumab has a dosing advantage over both these rivals as it can be delivered just twice a year.
-
Medimmune-born Viela files $150m IPO, eyes first product launch
The money raised in the IPO will give the Maryland-based biotech the financial muscle it needs to start building the commercial platform for its lead drug inebilizumab, which has just ... Inebilizumab is an anti-CD19 antibody developed initially to treat
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Medical Editor
-
Competitive
-
Healthcare Account Director
-
Competitive
-
Healthcare Lead Copywriter
-
Competitive
-
Healthcare Senior Account Manager
-
Competitive
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
- Sinovac’s COVID-19 vaccine appears safe in older adults
- Celltrion’s investigational mAb cuts COVID-19 recovery time
- COVID-19 vaccine developers respond to new strain
- Inovio plans late-stage COVID-19 vaccine study in second quarter 2021
- bluebird bio to separate oncology and rare diseases units
- AZ’s COVID-19 vaccine trial to continue after Brazilian volunteer death
- Live Webinar: COVID-19 Has Changed Live Events Forever!
- New hire and promotions announced at Evoke KYNE
- Amgen strikes $240m autoimmune deal with Evoq Therapeutics
- Lucid Group bolster its talent with a further twelve new starters for 2021
- UK pharmacies to begin administering COVID-19 vaccinations
- PHE study finds people who have had COVID-19 can still transmit the virus
PMHub
Oncosec
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...
Latest intelligence
- AstraZeneca’s focus on diagnosing and managing chronic kidney disease
- People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...
- Delphi Technique Virtual Co-creation: A Customer Story
- How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints....
- Three ways AI will change healthcare in the next decade
- Looking forward, there is no doubt that AI will continue to take centre stage in global healthcare initiatives...
Quick links
Infographics
